GlobeNewsWire
05 Aug 2026, 23:45 UTC · 11w ago
UPDATE - LifeMD Reports Second Quarter 2026 Results
Impact · against what's priced in
LFMD is experiencing a transition period where a shift toward higher-quality, long-term patient relationships and branded GLP-1s is temporarily squeezing margins, though 2026 year-end targets provide a new valuation floor. HALO sees marginal positive sentiment from the progress of the XYOSTED collaboration.
- LFMD+0.20
No priced-in read yet
- In context
The company provides concrete new targets to exit 2026 with a $250 million revenue run rate and $22 million in adjusted EBITDA, while shifting its patient base toward multi-month packages (from 25% to 85%).
Read from the article alone
